レブリミド®カプセル剤の特別使用結果調査（新規診断多発性骨髄腫患者対象）

基本情報

NCT ID

NCT02741544

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

578

治験依頼者名

Celgene

概要

To understand the safety and efficacy of Revlimid® 2.5mg and 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end at the time when the planned number of patients to be enrolled is reached. 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end on the day when the approval condition related to all-case surveillance is terminated.

対象疾患

依頼者（Sponsor）

実施施設 (2)